Related Experiment Video

Updated: Mar 16, 2026

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

10.8K

Association between interleukin-17A polymorphism and coronary artery disease susceptibility in the Chinese Han

G B Su1, X L Guo1, X C Liu1

  • 1Department of Cardiothoracic Surgery, First Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, China.

Genetics and Molecular Research : GMR
|August 16, 2016
PubMed

Insights

Genetic variations in the Interleukin-17A (IL-17A) gene are linked to increased susceptibility to coronary artery disease (CAD). Specific IL17A polymorphisms may play a role in CAD development, highlighting IL-17A

Area of Science:

  • Immunogenetics
  • Cardiovascular Disease Research
  • Molecular Biology

Background:

  • Coronary artery disease (CAD) presents a significant global health challenge, with rising incidence and mortality rates in China.
  • Interleukin-17A (IL-17A), a pro-inflammatory cytokine produced by T cells, is implicated in CAD pathogenesis.
  • Genetic variations within the IL17A gene may influence an individual's risk for developing CAD.

Purpose of the Study:

  • To investigate the association between specific single nucleotide polymorphisms (SNPs) in the IL17A gene and the risk of CAD.
  • To analyze the role of functional IL17A polymorphisms in the development of coronary artery disease.

Main Methods:

  • A case-control study was conducted analyzing five functional SNPs (rs8193037, rs8193036, rs3819024, rs2275913, and rs3748067) in the IL17A gene.
  • Allelic and genotypic frequencies of IL17A SNPs were compared between CAD patients and healthy controls.
  • Linkage disequilibrium and haplotype analysis were performed for identified SNPs.

Main Results:

  • Significant differences in allelic and genotypic frequencies were observed for IL17A polymorphisms rs8193037 and rs8193036 in CAD patients compared to controls.
  • A lower frequency of the A allele for rs8193037 and the T allele for rs8193036 was found in CAD subjects, indicating a potential protective effect or altered risk.
  • Analysis revealed significant linkage disequilibrium and a lower frequency of the T-G-G-A haplotype in CAD patients.

Conclusions:

  • IL17A gene polymorphisms are associated with susceptibility to coronary artery disease.
  • These findings support the involvement of Interleukin-17A dysfunction in the pathophysiological mechanisms underlying CAD.
  • Specific IL17A variants may serve as genetic markers for CAD risk assessment.

More Related Videos

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment07:26

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

Published on: July 18, 2017

12.3K

Related Concept Videos

Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
16.5K
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
94
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
3.1K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
63